دورية أكاديمية

Body Mass Index and Plasma P-Selectin before Coronary Stenting Predict High Residual Platelet Reactivity at 6 Months on Dual Antiplatelet Therapy.

التفاصيل البيبلوغرافية
العنوان: Body Mass Index and Plasma P-Selectin before Coronary Stenting Predict High Residual Platelet Reactivity at 6 Months on Dual Antiplatelet Therapy.
المؤلفون: Golukhova EZ; Bakoulev Center for Cardiovascular Surgery, Academy of Medical Sciences, Moscow, Russia., Grigoryan MV, Ryabinina MN, Bulaeva NI, Serebruany VL
المصدر: Cardiology [Cardiology] 2018; Vol. 139 (2), pp. 132-136. Date of Electronic Publication: 2018 Jan 16.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Karger Country of Publication: Switzerland NLM ID: 1266406 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1421-9751 (Electronic) Linking ISSN: 00086312 NLM ISO Abbreviation: Cardiology Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, New York, Karger.
مواضيع طبية MeSH: Body Mass Index*, Coronary Artery Disease/*blood , P-Selectin/*blood , Platelet Activation/*drug effects , Platelet Aggregation Inhibitors/*administration & dosage, Adult ; Aged ; Biomarkers/blood ; Coronary Artery Disease/therapy ; Female ; Humans ; Male ; Middle Aged ; Percutaneous Coronary Intervention ; Prospective Studies
مستخلص: Background: High residual platelet reactivity (HRPR) during dual antiplatelet therapy (DAPT) may impact clinical outcomes following percutaneous coronary interventions (PCI). However, whether any biomarkers assessed before PCI at DAPT loading may predict delayed maintenance HRPR is not clear.
Objective: The aim of this study was to determine whether conventional clinical or laboratory indices at loading before stenting may predict HRPR at 6 months of maintenance DAPT.
Methods: The study was designed on a single-center prospective cohort, and included 94 pre-PCI patients. All patients underwent elective PCI with drug-eluting stent implantation, and received DAPT with aspirin and clopidogrel. Platelet reactivity was assessed with 5 μmol/L of adenosine diphosphate-induced light transmission aggregometry before PCI, but after 24 h of DAPT loading, and repeated at 6 months. Baseline clinical characteristics, CYP2C19 polymorphism, C-reactive protein, soluble P-selectin, CD40L, interleukin-6, PAI-1 levels, and von Willebrand factor activity were analyzed.
Results: The incidence (light transmission aggregometry <50%) of prestent HRPR was 16%. By univariate regression, body mass index (BMI; p = 0.02), total cholesterol (p = 0.01), low-density lipoproteins (p = 0.004), CYP2C19*2 allele carriage (p = 0.006), soluble P-selectin (p = 0.009), and von Willebrand factor (p = 0.04) were linked to future HRPR. However, multivariate regression analysis suggested that only BMI and P-selectin were independent predictors of HRPR.
Conclusions: Platelet reactivity before elective stenting is associated with numerous biomarkers; however, only BMI and soluble P-selectin were independent predictors of future HRPR during maintenance-phase DAPT. This may be important for future tailored antiplatelet strategies in patients with metabolic syndrome and diabetics.
(© 2018 S. Karger AG, Basel.)
فهرسة مساهمة: Keywords: Biomarkers; CYP2C19 polymorphism; Clinical outcomes; Coronary stenting; Platelet aggregation; Prediction
المشرفين على المادة: 0 (Biomarkers)
0 (P-Selectin)
0 (Platelet Aggregation Inhibitors)
تواريخ الأحداث: Date Created: 20180116 Date Completed: 20181003 Latest Revision: 20181004
رمز التحديث: 20221213
DOI: 10.1159/000485555
PMID: 29334682
قاعدة البيانات: MEDLINE
الوصف
تدمد:1421-9751
DOI:10.1159/000485555